Relationship between the serum CCL28 and SDF-1 levels and the condition and prognosis of chronic obstructive pulmonary disease complicated with pulmonary hypertension
10.3760/cma.j.cn431274-20231103-00506
- VernacularTitle:血清CCL28、SDF-1水平与慢性阻塞性肺疾病合并肺动脉高压患者病情及预后的关系
- Author:
Mei YAN
1
;
Jian LIU
;
Linlin LIU
Author Information
1. 济宁医学院附属医院呼吸与危重症医学科，济宁 272000
- Keywords:
Pulmonary disease, chronic obstructive;
Pulmonary arterial hypertension;
Chemokine CCL28;
Stromal cell derived factor-1
- From:
Journal of Chinese Physician
2024;26(10):1535-1539
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between the expression levels of CC chemokine ligand 28 (CCL28) and stromal cell derived factor-1 (SDF-1) in serum and the condition and therapeutic effect of chronic obstructive pulmonary disease (COPD) complicated with pulmonary hypertension.Methods:A total of 98 COPD patients with pulmonary hypertension admitted to the Affiliated Hospital of Jining Medical College from January 2019 to June 2023 were selected as case group A, 100 COPD patients without pulmonary hypertension were selected as case group B, and 100 healthy volunteers were selected as control group. The serum levels of CCL28 and SDF-1 in the three groups were compared, and the correlation between the serum levels of CCL28 and SDF-1 in patients with COPD combined with pulmonary hypertension and pulmonary artery pressure parameters and pulmonary function indexes was analyzed, and the changes of various indexes in patients with COPD combined with pulmonary hypertension were compared before and after treatment.Results:The levels of CCL28 and SDF-1 in the case group A were significantly higher than those in the case group B and the control group, with statistical significance (all P<0.05). The levels of CCL28 and SDF-1 in the case group B were significantly higher than those in the control group, and the differences were statistically significant (all P<0.05). The mean pulmonary artery pressure (mPAP), pulmonary artery wedge pressure, pulmonary vascular resistance, arterial partial pressure of carbon dioxide (PaCO 2) and percentage of residual total gas volume (RV/TLC) in the case group A were higher than those in the case group B. The partial pressure of arterial blood oxygen (PaO 2), the percentage of forced expiratory volume in the first second to the predicted value (FEV 1 pred%), and the pulmonary carbon monoxide dispersion (DLCO) were lower than those of case group B, and the differences were statistically significant (all P<0.05). Serum CCL28 and SDF-1 levels in the case group A were positively correlated with mPAP and pulmonary wedge pressure (all P<0.05), but not with FEV 1 pred%, RV/TLC and DLCO (all P>0.05). After treatment, the serum levels of CCL28 and SDF-1, mPAP, pulmonary wedge pressure, pulmonary vascular resistance, PaCO 2 and RV/TLC in case group A were significantly decreased compared with before treatment, while PaO 2, FEV 1 pred% and DLCO were significantly increased compared with before treatment, with statistical significance (all P<0.05). Conclusions:The serum levels of CCL28 and SDF-1 in patients with COPD combined with pulmonary hypertension are significantly increased, and are closely related to the severity of pulmonary hypertension. After active treatment, the serum levels of CCL28 and SDF-1 in patients will be significantly reduced.
